Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOK583A1 (Biosimilar Aflibercept) vs Eylea in Neovascular AMD
NCT04864834Phase 3Completed
- Sponsor
- Sandoz
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 16
01
Overview
A Phase 3 trial of 9MW0813 in neovascular age-related macular degeneration (NVAMD), sponsored by Sandoz. Started May 2021; status: completed.
02
Drugs
9MW0813
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04864834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864834.